The Global Antibiotic Research and Development Partnership (GARDP) has signed a multi-partner agreement with Eisei Co., Ltd. and Takeda Pharmaceutical Company Limited which allows GARDP to access and screen the chemical libraries of both companies. The underlying hope: to discover novel compounds with antibacterial activity to tackle serious bacterial infections. The selected compounds have emerged from Eisai and Takeda’s latest medicinal chemistry efforts and have not been screened for antibacterial activity before.
“GARDP is very excited about this partnership. Not only can partnerships like this accelerate the discovery of new antibiotics, they can also support the pharmaceutical sector in staying engaged in antibiotic R&D,” said Dr. Seamus O’Brien, Research and Development Director at GARDP and one of the speakers of the AMR conference. “Overcoming antibacterial resistance is key to achieve universal health coverage. GARDP’s approach allows us to develop a drug from early exploratory to preclinical and clinical studies all the way to patients.”
Together with partners, GARDP will organise a pre-conference workshop at the AMR conference titled “Resistance testing – beyond serial pass experiments”. The workshop is jointly organised by Novo Repair Impact Fund, CARB-X, GARDP and Wellcome Trust.
Read the Press Release